For example, the humanized monoclonal antibodies against Her 2 receptor (trastuzumab, Herceptin®) [36] and those against vascular endothelial growth factor (VEGF) a ligand for VEGF receptor 2 (bevacizumab, Avastin®) [37], have emerged as treatments for patients with advanced stages of breast cancer. This evidence concerns the gene VEGFA and breast cancer.